 13. Prior therapy with an anti-Programmed cell death protein 1 anti-PD-1, anti-PD-L1, anti-Programmed cell death-ligand 2 anti-PD-L2, anti-CD137 4-1BB ligand, a member of the Tumor Necrosis Factor Receptor TNFR family, or anti-Cytotoxic T-lymphocyte-associated antigen-4 anti-CTLA-4 antibody including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways 